Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Endocrinology
•
HIV & AIDS
•
Primary Care
What patient-specific factors would influence your decision to initiate semaglutide therapy in patients with HIV-associated lipohypertrophy?
Answer from: at Academic Institution
I would consider it if the patient had diabetes. But there is not much data on this question.
Comments
at George Washington School Of Medicine
Is there any data?
13807
Sign In
or
Register
to read more
25057
Related Questions
Would you consider using long-acting injectable cabotegravir/rilpivirine for pregnant women with HIV?
Would you recommend switching from an integrase strand transfer inhibitor-based regimen to a different antiretroviral regimen, or would you instead add weight loss medications for a person with HIV experiencing weight gain that has not improved with lifestyle changes?
Can inflammatory arthritis develop in patients with a history of chronic hepatitis B?
How do you balance diagnostic stewardship and high value cost-conscious care when working up a patient with newly diagnosed HIV/AIDS admitted to the ICU with shortness of breath who most likely has PJP pneumonia or cryptococcal infection but is at risk of multiple other pathogens?
How do you evaluate for an ascending UTI in a patient with a urostomy?
How do you consider sending fungal studies in a patient with pneumonia?
Do you favor a certain NRTI to pair with dolutegravir and lamivudine in persons with HIV to minimize the risk of resistance to dolutegravir?
Would you consider using thalidomide for treating HIV-associated tuberculosis-IRIS in adult patients who have poor response or intolerance to corticosteroid therapy?
How do you assess and adjust treatment in patients who develops hypothyroidism after being on lithium for several years?
Outside of teplizumab, what therapies do you recommend for preserving beta cell function in patients with early stage type 1 diabetes mellitus?
Is there any data?